Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate

The Pharmacogenomics Journal volume 13, pages 476–480 (2013)Cite this article

Subjects

Abstract

Carboxylesterase 1 is the enzyme involved in methylphenidate (MPH) metabolism. The aim of this study was to evaluate the association between a −75 T>G polymorphism and appetite reduction in children with attention-deficit/hyperactivity disorder (ADHD). A sample of 213 children with ADHD was investigated. The primary outcome was appetite reduction measured by the Barkley Stimulant Side Effect Rating Scale applied at baseline, at 1 and 3 months of treatment. MPH doses were augmented until no further clinical improvement or significant adverse events occurred. The G allele presented a trend for association with appetite reduction scores (P=0.05). A significant interaction between the G allele and treatment over time for appetite reduction scores was also observed (P=0.03). The G allele carriers presented a higher risk for appetite reduction worsening when compared with T allele homozygotes (odds ratio=3.47, P=0.01). The present results suggest an influence of carboxylesterase 1 −75 T>G polymorphism on the worsening of appetite reduction with MPH treatment in youths with ADHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA . The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007a; 164: 942–948.

    Article  PubMed  Google Scholar 

  2. Spencer TJ . ADHD treatment across the life cycle. J Clin Psychiatry 2004; 65: 22–26.

    Article  CAS  PubMed  Google Scholar 

  3. Wolraich ML, McGuinn L, Doffing M . Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations. Drug Saf 2007; 30: 17–26.

    Article  CAS  PubMed  Google Scholar 

  4. Han DD, Gu HH . Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 2006; 6: 6.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Szobot CM, Roman T, Hutz MH, Genro JP, Shih MC, Hoexter MQ et al. Molecular imaging genetics of methylphenidate response in ADHD and substance use comorbidity. Synapse 2011; 65: 154–159.

    Article  CAS  PubMed  Google Scholar 

  6. Kieling C, Genro JP, Hutz MH, Rohde LA . A current update on ADHD pharmacogenomics. Pharmacogenomics 2010; 11: 407–419.

    Article  CAS  PubMed  Google Scholar 

  7. Polanczyk G, Bigarella MP, Hutz MH, Rohde LA . Pharmacogenetic approach for a better drug treatment in children. Curr Pharm Des 2010; 16: 2462–2473.

    Article  CAS  PubMed  Google Scholar 

  8. McGough J, McCracken J, Swanson J, Riddle M, Kollins S, Greenhill L et al. Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006; 45: 1314–1322.

    Article  PubMed  Google Scholar 

  9. McGough JJ, McCracken JT, Loo SK, Manganiello M, Leung MC, Tietjens JR et al. A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2009; 48: 1155–1164.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Markowitz JS, Straughn AB, Patrick KS . Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy 2003; 23: 1281–1299.

    Article  CAS  PubMed  Google Scholar 

  11. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 2008; 82: 1241–1248.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Nemoda Z, Angyal N, Tarnok Z, Gadoros J, Sasvari-Szekely M . Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology 2009; 57: 731–733.

    Article  CAS  PubMed  Google Scholar 

  13. Yamada S, Richardson K, Tang M, Halaschek-Wiener J, Cook VJ, Fitzgerald JM et al. Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity. Pharmacogenomics J 2010; 10: 524–536.

    Article  CAS  PubMed  Google Scholar 

  14. Taylor E, Döpfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J et al. European clinical guidelines for hyperkinetic disorder—first upgrade. Eur Child Adolesc Psychiatry 2004; 13: I7–30.

    Article  PubMed  Google Scholar 

  15. Schertz M, Adesman AR, Alfieri NE, Bienkowski RS . Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication. Pediatrics 1996; 98: 763–769.

    CAS  PubMed  Google Scholar 

  16. Pliszka S . Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 894–921.

    Article  PubMed  Google Scholar 

  17. Graham J, Coghill D . Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 2008; 22: 213–237.

    Article  CAS  PubMed  Google Scholar 

  18. Efron D, Jarman F, Barker M . Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 1997; 100: 662–666.

    Article  CAS  PubMed  Google Scholar 

  19. Wigal T, Greenhill L, Chuang S, McGough J, Vitiello B, Skrobala A et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry 2006; 45: 1294–1303.

    Article  PubMed  Google Scholar 

  20. Zachor DA, Roberts AW, Hodgens JB, Isaacs JS, Merrick J . Effects of long-term psychostimulant medication on growth of children with ADHD. Res Dev Disabil 2006; 27: 162–174.

    Article  PubMed  Google Scholar 

  21. Zeni CP, Guimarães AP, Polanczyk GV, Genro JP, Roman T, Hutz MH et al. No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 391–394.

    Article  PubMed  Google Scholar 

  22. Polanczyk G, Zeni C, Genro JP, Guimarães AP, Roman T, Hutz MH et al. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2007b; 64: 218–224.

    Article  CAS  PubMed  Google Scholar 

  23. Barkley RA . Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. Guilford Press: New York, 1990.

    Google Scholar 

  24. Martins S, Tramontina S, Polanczyk G, Eizirik M, Swanson JM, Rohde LA . Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial. J Child Adolesc Psychopharmacol 2004; 14: 195–206.

    Article  PubMed  Google Scholar 

  25. Rohde LA . ADHD in Brazil: the DSM-IV criteria in a culturally different population. J Am Acad Child Adolesc Psychiatry 2002; 41: 1131–1133.

    Article  PubMed  Google Scholar 

  26. Lahiri DK, Nurnberger JI . A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991; 19: 5444.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry 1993; 50: 739–750.

    Article  CAS  PubMed  Google Scholar 

  28. Mallinckrodt CH, Clark WS, David SR . Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001; 11: 9–21.

    Article  CAS  PubMed  Google Scholar 

  29. Gueorguieva R, Krystal JH . Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 2004; 61: 310–317.

    Article  PubMed  Google Scholar 

  30. Froehlich TE, Epstein JN, Nick TG, Melguizo Castro MS, Stein MA, Brinkman WB et al. Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011; 50: 1129–1139.e1122.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Cohen J, Cohen P, West SG, Aiken LS . Applied Multiple Regression/Correlation Analysis for the Behavioral Science. Mahwah: Erlbaum, NJ, 2003.

    Google Scholar 

  32. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 1313–1323.

    Article  CAS  PubMed  Google Scholar 

  33. Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003; 112: e404.

    Article  PubMed  Google Scholar 

  34. Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 180–187.

    Article  CAS  PubMed  Google Scholar 

  35. Barkley RA, McMurray MB, Edelbrock CS, Robbins K . Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990; 86: 184–192.

    CAS  PubMed  Google Scholar 

  36. Leddy JJ, Epstein LH, Jaroni JL, Roemmich JN, Paluch RA, Goldfield GS et al. Influence of methylphenidate on eating in obese men. Obes Res 2004; 12: 224–232.

    Article  CAS  PubMed  Google Scholar 

  37. Hammerness P, Georgiopoulos A, Doyle RL, Utzinger L, Schillinger M, Martelon M et al. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol 2009; 19: 493–499.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Sonuga-Barke EJ, Coghill D, Wigal T, DeBacker M, Swanson J . Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control. J Child Adolesc Psychopharmacol 2009; 19: 683–690.

    Article  PubMed  Google Scholar 

  39. Lee J, Grizenko N, Bhat V, Sengupta S, Polotskaia A, Joober R . Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD. BMC Psychiatry 2011; 11: 70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Davis C, Levitan RD, Kaplan AS, Carter J, Reid C, Curtis C et al. Dopamine transporter gene (DAT1) associated with appetite suppression to methylphenidate in a case-control study of binge eating disorder. Neuropsychopharmacology 2007; 32: 2199–2206.

    Article  CAS  PubMed  Google Scholar 

  41. Leddy JJ, Waxmonsky JG, Salis RJ, Paluch RA, Gnagy EM, Mahaney P et al. Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths. J Child Adolesc Psychopharmacol 2009; 19: 127–136.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brazil), Coordenação de Pessoal de Nível Superior (CAPES, Brazil), Fundação de Amparo a Pesquisa de São Paulo (FAPESP) and Financiadora de Estudos e Projetos (FINEP, Brazil) for financial support.

Author information

Authors and Affiliations

  1. Department of Genetics, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

    E M Bruxel, A Salatino-Oliveira, J P Genro & M H Hutz

  2. Division of Child and Adolescent Psychiatry, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

    C P Zeni, G V Polanczyk, R Chazan & L A Rohde

  3. Instituto de Psiquiatria do Desenvolvimento para a Infância e Adolescência, Porto Alegre, Brazil

    L A Rohde

Authors
  1. E M Bruxel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Salatino-Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J P Genro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C P Zeni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G V Polanczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Chazan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L A Rohde
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M H Hutz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M H Hutz.

Ethics declarations

Competing interests

Dr Rohde was on the speakers’ bureau and/or acted as consultant for Eli-Lilly, Janssen-Cilag, Novartis and Shire in the last 3 years (less than U$ 10 000 per year and reflecting less than 5% of his gross income per year). He also received travel awards (air tickets and hotel) for taking part of two child psychiatric meetings from Novartis and Janssen-Cilag in 2010. The ADHD and Juvenile Bipolar Disorder Outpatient Programs chaired by him received unrestricted educational and research support from the following pharmaceutical companies in the last 3 years: Abbott, Bristol-Myers Squibb, Eli-Lilly, Janssen-Cilag, Novartis and Shire. All other authors report no biomedical financial interest or potential conflict of interest.

Additional information

Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website

Supplementary information

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bruxel, E., Salatino-Oliveira, A., Genro, J. et al. Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate. Pharmacogenomics J 13, 476–480 (2013). https://doi.org/10.1038/tpj.2012.25

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2012.25

Keywords

This article is cited by

Search

Advanced search

Quick links